Skip to main content

Skin Ulcer Venous Stasis Chronic

3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

RHEACELL
RHEACELLGermany - Heidelberg
3 programs
2
1
allo-APZ2-CVUPhase 21 trial
APZ2 applicationPhase 1/21 trial
allo-APZ2-CVUPhase 1/21 trial
Active Trials
NCT02742844Terminated13Est. Jan 2019
NCT03257098Completed31Est. Jun 2020
NCT04971161Completed159Est. Nov 2025
Inotec AMD
Inotec AMDUK - Cambridge
1 program
NatroxTM DeviceN/A1 trial
Active Trials
NCT01913704Withdrawn0Est. Oct 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RHEACELLallo-APZ2-CVU
RHEACELLallo-APZ2-CVU
RHEACELLAPZ2 application
Inotec AMDNatroxTM Device

Clinical Trials (4)

Total enrollment: 203 patients across 4 trials

NCT04971161RHEACELLallo-APZ2-CVU

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

Start: Aug 2021Est. completion: Nov 2025159 patients
Phase 2Completed
NCT03257098RHEACELLallo-APZ2-CVU

Allogeneic ABCB5-positive Stem Cells for Treatment of CVU

Start: Nov 2017Est. completion: Jun 202031 patients
Phase 1/2Completed
NCT02742844RHEACELLAPZ2 application

Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers

Start: Aug 2016Est. completion: Jan 201913 patients
Phase 1/2Terminated
NCT01913704Inotec AMDNatroxTM Device

Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers

Start: Oct 2012Est. completion: Oct 20140
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.